" class="no-js "lang="en-US"> LumiraDx - Medtech Alert
Monday, September 15, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
LumiraDx | Pharmtech Focus

LumiraDx

About LumiraDx

LumiraDx

LumiraDx recognizes the need to provide more effective, cost-efficient healthcare for everyone.

We make diagnostic-led care simpler and more accessible with smarter connected diagnostics and diagnostic-led care solutions to enable better outcomes: better health, better experiences and better value.

Founded in 2014 by a group of entrepreneurs with a successful track record of building and scaling diagnostics and health IT businesses, LumiraDx is now expanding the number of representatives and subsidiaries in all continents.

Related Story

COVID-19

 LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira

LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System

June 13 2022

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that it has […]

COVID-19

 LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking | Pharmtech Focus

LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking

May 20 2022

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its SARS-CoV-2 Ag Ultra […]

COVID-19

 LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant | Pharmtech Focus

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant

January 14 2022

LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing […]

COVID-19

 LumiraDx Announces the Intended Use for its FDA EUA Authorized High Sensitivity COVID-19 Antigen Test has been Expanded to Include Testing of Asymptomatic Individuals | Pharmtech Focus

LumiraDx Announces the Intended Use for its FDA EUA Authorized High Sensitivity COVID-19 Antigen Test has been Expanded to Include Testing of Asymptomatic Individuals

November 2 2021

Today, LumiraDx (Nasdaq: LMDX) a next-generation point of care (POC) diagnostics company announced that the intended use for its Food […]